Sinusitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 111 Published: June 30, 2022 Report Code: GDGMDHC22198IDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    iSpeech

The Sinusitis pipeline market report provides a comprehensive overview of the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects.

Sinusitis Pipeline Drugs Market by Key Targets

In the Sinusitis pipeline drugs market, the key targets are Glucocorticoid Receptor, Interleukin 4 Receptor Subunit Alpha, Interleukin 5, Thymic Stromal Lymphopoietin, Calcitonin Gene Related Peptide Type 1 Receptor, P Selectin, 23S Ribosomal RNA, 30S Ribosomal Subunit, Beta Lactamase, and C-C Chemokine Receptor Type 4.

Key Targets in the Sinusitis Pipeline Drugs Market

Key Targets in the Sinusitis Pipeline Drugs Market

For more target insights, download a free report sample

Key MoA in the Sinusitis Pipeline Drugs Market

Glucocorticoid Receptor Agonist has the highest share in the Sinusitis pipeline drugs market. The other key mechanisms of action are Interleukin 4 Receptor Subunit Alpha Antagonist, Interleukin 5 Inhibitor, Thymic Stromal Lymphopoietin Inhibitor, Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, P Selectin Inhibitor, 23S Ribosomal RNA Inhibitor, 30S Ribosomal Subunit Inhibitor, Beta Lactamase Inhibitor, and C-C Chemokine Receptor Type 4 Antagonist.

Sinusitis Pipeline Drugs Market Analysis, by MoA

Sinusitis Pipeline Drugs Market Analysis, by MoA

To get more insights on key MoA, download a free sample report

Sinusitis Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Sinusitis pipeline drug market are subcutaneous, nasal, intravenous, oral, ophthalmic, transmucosal, and topical. Subcutaneous has the maximum number of pipeline products.

Sinusitis Pipeline Drugs Market Analysis, by RoA

Sinusitis Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Sinusitis Pipeline Drugs Market

The key molecule types in the Sinusitis pipeline drugs market are small molecule, monoclonal antibody, biologic, peptide, and synthetic peptide. Small molecule has the maximum number of pipeline products.

Sinusitis Pipeline Drugs Market, by Molecule Types

Sinusitis Pipeline Drugs Market, by Molecule Types

To get more insights on key molecule types, download a free sample report

Major Companies in the Sinusitis Pipeline Drugs Market

Some of the major companies in the Sinusitis pipeline drugs market are GSK plc, KeyMed Biosciences Inc, Lyra Therapeutics Inc, Biohaven Pharmaceutical Holding Company Ltd, GlycoMira Therapeutics Inc, 3SBio Inc, Amgen Inc, Amytrx Therapeutics Inc, AnaptysBio Inc, Aodh Lifesciences Pvt Ltd, and Argenx SE.

Sinusitis Pipeline Drugs Market, by Major Companies

Sinusitis Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Sinusitis Pipeline Drugs Market Overview

Key Targets Glucocorticoid Receptor, Interleukin 4 Receptor Subunit Alpha, Interleukin 5, Thymic Stromal Lymphopoietin, Calcitonin Gene Related Peptide Type 1 Receptor, P Selectin, 23S Ribosomal RNA, 30S Ribosomal Subunit, Beta Lactamase, and C-C Chemokine Receptor Type 4
Key Mechanisms of Action Glucocorticoid Receptor Agonist, Interleukin 4 Receptor Subunit Alpha Antagonist, Interleukin 5 Inhibitor, Thymic Stromal Lymphopoietin Inhibitor, Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, P Selectin Inhibitor, 23S Ribosomal RNA Inhibitor, 30S Ribosomal Subunit Inhibitor, Beta Lactamase Inhibitor, and C-C Chemokine Receptor Type 4 Antagonist
Key Routes of Administration Subcutaneous, Nasal, Intravenous, Oral, Ophthalmic, Transmucosal, and Topical
Key Molecule Types Small Molecule, Monoclonal Antibody, Biologic, Peptide, and Synthetic Peptide
Major Companies GSK plc, KeyMed Biosciences Inc, Lyra Therapeutics Inc, Biohaven Pharmaceutical Holding Company Ltd, GlycoMira Therapeutics Inc, 3SBio Inc, Amgen Inc, Amytrx Therapeutics Inc, AnaptysBio Inc, Aodh Lifesciences Pvt Ltd, and Argenx SE

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sinusitis
  • The pipeline guide reviews pipeline therapeutics for Sinusitis by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sinusitis therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sinusitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Sinusitis

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sinusitis
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sinusitis pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

3SBio Inc

Amgen Inc

Amytrx Therapeutics Inc

AnaptysBio Inc

Aodh Lifesciences Pvt Ltd

Argenx SE

Beijing FuKangren Bio-pharm Tech Co Ltd

Biohaven Pharmaceutical Holding Company Ltd

Furen Pharmaceutical Group Co Ltd

GeneOne Life Science Inc

Genrix (Shanghai) Biopharmaceutical Co Ltd

GlycoMira Therapeutics Inc

GSK plc

Insmed Inc

IVIEW Therapeutics Inc

Jantar GmbH

JiangSu Qyuns Therapeutics Co Ltd

KeyMed Biosciences Inc

Kyowa Kirin Co Ltd

Lanier Biotherapeutics Inc

Lyra Therapeutics Inc

Maxwell Biosciences Inc

Merck & Co Inc

Nexeos Bio

Nota Laboratories LLC

OptiNose Inc

Oticara Inc

Pfizer Inc

ProclaRx LLC

Quorum Innovations LLC

RAPT Therapeutics Inc

Recce Pharmaceuticals Ltd

Regeneron Pharmaceuticals Inc

SaNOtize Research and Development Corp

Shandong Boan Biotechnology Co Ltd

Suzhou Connect Biopharmaceuticals Ltd

Synermore Biologics Co Ltd

Trellis Bioscience Inc

Wuhan Yicheng Biotechnology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sinusitis – Overview

Sinusitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Sinusitis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sinusitis – Companies Involved in Therapeutics Development

Sinusitis – Drug Profiles

Sinusitis – Dormant Projects

Sinusitis – Discontinued Products

Sinusitis – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Sinusitis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Sinusitis – Pipeline by 3SBio Inc, 2022

Sinusitis – Pipeline by Amgen Inc, 2022

Sinusitis – Pipeline by Amytrx Therapeutics Inc, 2022

Sinusitis – Pipeline by AnaptysBio Inc, 2022

Sinusitis – Pipeline by Aodh Lifesciences Pvt Ltd, 2022

Sinusitis – Pipeline by Argenx SE, 2022

Sinusitis – Pipeline by Beijing FuKangren Bio-pharm Tech Co Ltd, 2022

Sinusitis – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022

Sinusitis – Pipeline by Furen Pharmaceutical Group Co Ltd, 2022

Sinusitis – Pipeline by GeneOne Life Science Inc, 2022

Sinusitis – Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2022

Sinusitis – Pipeline by GlycoMira Therapeutics Inc, 2022

Sinusitis – Pipeline by GSK plc, 2022

Sinusitis – Pipeline by Insmed Inc, 2022

Sinusitis – Pipeline by IVIEW Therapeutics Inc, 2022

Sinusitis – Pipeline by Jantar GmbH, 2022

Sinusitis – Pipeline by JiangSu Qyuns Therapeutics Co Ltd, 2022

Sinusitis – Pipeline by KeyMed Biosciences Inc, 2022

Sinusitis – Pipeline by Kyowa Kirin Co Ltd, 2022

Sinusitis – Pipeline by Lanier Biotherapeutics Inc, 2022

Sinusitis – Pipeline by Lyra Therapeutics Inc, 2022

Sinusitis – Pipeline by Maxwell Biosciences Inc, 2022

Sinusitis – Pipeline by Merck & Co Inc, 2022

Sinusitis – Pipeline by Nexeos Bio, 2022

Sinusitis – Pipeline by Nota Laboratories LLC, 2022

Sinusitis – Pipeline by OptiNose Inc, 2022

Sinusitis – Pipeline by Oticara Inc, 2022

Sinusitis – Pipeline by Pfizer Inc, 2022

Sinusitis – Pipeline by ProclaRx LLC, 2022

Sinusitis – Pipeline by Quorum Innovations LLC, 2022

Sinusitis – Pipeline by RAPT Therapeutics Inc, 2022

Sinusitis – Pipeline by Recce Pharmaceuticals Ltd, 2022

Sinusitis – Pipeline by Regeneron Pharmaceuticals Inc, 2022

Sinusitis – Pipeline by SaNOtize Research and Development Corp, 2022

Sinusitis – Pipeline by Shandong Boan Biotechnology Co Ltd, 2022

Sinusitis – Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2022

Sinusitis – Pipeline by Synermore Biologics Co Ltd, 2022

Sinusitis – Pipeline by Trellis Bioscience Inc, 2022

Sinusitis – Pipeline by Wuhan Yicheng Biotechnology Co Ltd, 2022

Sinusitis – Dormant Projects, 2022

Sinusitis – Dormant Projects, 2022 (Contd..1)

Sinusitis – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Sinusitis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

In the Sinusitis pipeline drugs market the key targets are Glucocorticoid Receptor, Interleukin 4 Receptor Subunit Alpha, Interleukin 5, Thymic Stromal Lymphopoietin, Calcitonin Gene Related Peptide Type 1 Receptor, P Selectin, 23S Ribosomal RNA, 30S Ribosomal Subunit, Beta Lactamase, and C-C Chemokine Receptor Type 4.

In the Sinusitis pipeline drugs market the key mechanisms of action are Glucocorticoid Receptor Agonist, Interleukin 4 Receptor Subunit Alpha Antagonist, Interleukin 5 Inhibitor, Thymic Stromal Lymphopoietin Inhibitor, Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, P Selectin Inhibitor, 23S Ribosomal RNA Inhibitor, 30S Ribosomal Subunit Inhibitor, Beta Lactamase Inhibitor, and C-C Chemokine Receptor Type 4 Antagonist.

The key routes of administration in the Sinusitis pipeline drug market Subcutaneous, Nasal, Intravenous, Oral, Ophthalmic, Transmucosal, and Topical. Subcutaneous has the maximum number of pipeline products.

The key molecule types in the Sinusitis pipeline drug market are Small Molecule, Monoclonal Antibody, Biologic, Peptide, and Synthetic Peptide.

In the Sinusitis pipeline drugs market the major companies are GSK plc, KeyMed Biosciences Inc, Lyra Therapeutics Inc, Biohaven Pharmaceutical Holding Company Ltd, GlycoMira Therapeutics Inc, 3SBio Inc, Amgen Inc, Amytrx Therapeutics Inc, AnaptysBio Inc, Aodh Lifesciences Pvt Ltd, and Argenx SE.

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.